PULSE the living trend engine
◼ Archived Business 🔮 PULSE predicts: fades by tomorrow

Lilly unveils first clinical data behind $2.3B Ajax deal, showing JAK inhibitor works ‘right out of the gate’

Eli Lilly reports positive initial Phase 1 clinical data for its $2.3 billion acquisition of Ajax Therapeutics' myelofibrosis treatment.

8sources
8articles
6velocity
+0%since first seen
57d agofirst detected

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

The brief

Eli Lilly has released the first clinical findings regarding AJX-101, a type II JAK2 inhibitor developed by Ajax Therapeutics. Data from the Phase 1 study indicates that the drug, also referred to as AJ1-11095, reduced spleen size and alleviated symptoms in patients with previously treated myelofibrosis.

Coverage from outlets including BioSpace, Yahoo Finance, and Fierce Biotech highlights the drug's efficacy as a potential expansion of Lilly’s pipeline beyond obesity treatments. These reports emphasize that the findings are being presented at the 2026 EHA Annual Meeting, noting the clinical performance of the treatment among patients who had previously used type I JAK inhibitors.

Future developments hinge on subsequent clinical trial phases. Coverage does not yet specify a timeline for further testing or potential regulatory submissions for the therapy.

Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 54d ago.

Quick answers

What is the primary function of the drug AJX-101?

It is a first-in-class type II JAK2 inhibitor designed to treat myelofibrosis.

How much did Eli Lilly pay for the acquisition of Ajax?

Eli Lilly acquired Ajax for $2.3 billion.

Where are these study results being shared?

The data is being presented at the 2026 EHA Annual Meeting.

Coverage (8)

Topics

Eli Lilly Ajax Therapeutics Myelofibrosis AJX-101 EHA Annual Meeting

Related trends

↓ Cooling Health

Lilly's weight-loss pill gets UK regulator's nod

The UK medicines regulator has approved a new once-daily weight-loss pill from Eli Lilly, offering an oral alternative to injectable GLP-1 treatments.

7 sources 7 articles v 5 3h ago